Quick Answer
Aardvark Therapeutics, Inc. reported Stockholders Equity of $106.63 million for fiscal year 2025.
Aardvark Therapeutics, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $106.63M | +295.1% |
| 2024 | -$54.64M | -57.0% |
| 2023 | -$34.80M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $122.38M | +365.0% | -10.6% |
| June 30, 2025 | $136.93M | +423.7% | -9.1% |
| March 31, 2025 | $150.69M | +508.2% | +375.8% |
| December 31, 2024 | -$54.64M | -57.0% | -18.3% |
| September 30, 2024 | -$46.17M | — | -9.1% |
| June 30, 2024 | -$42.31M | — | -14.6% |
| March 31, 2024 | -$36.91M | — | -6.1% |
| December 31, 2023 | -$34.80M | — | — |
- Aardvark Therapeutics, Inc. showed an increase of +295.1% in Stockholders Equity compared to the prior fiscal year.
- Over the 2023–2025 period, Aardvark Therapeutics, Inc.’s stockholders equity has grown by 406.4% (from -$34.80 million to $106.63 million).
- The most recent figure is from Aardvark Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 23, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: